Baldo Scassellati Sforzolini, MD, PhD, MBA, Galderma’s global head of research, recently presented data on RelabotulinumtoxinA, a six-month neuromodulator for wrinkles. The READY-4 trial confirms its safety and efficacy, supported by PEARL Technology across diverse groups. Here, Sforzolini shares his findings.

Preoperative Botox injections are a useful test for predicting how well patients with chronic migraine will respond to nerve decompression surgery, reports a study in the May issue of Plastic and Reconstructive Surgery.

Evolus, Inc. announces positive Phase 2 trial results, presented at the 2023 ASDS Annual Meeting, showing that the “extra-strength” 40U dose of Jeuveau provides 26 weeks of extended aesthetic benefits with a favorable safety profile compared to control groups, indicating its potential for longer-lasting results in aesthetic treatments.

According to an analysis of the U.K.’s cosmetic injectables industry by University College London researchers, 68% of cosmetic practitioners who are administering injections, such as Botox are not qualified medical doctors.

The U.S. FDA is updating its page on dermal fillers to include information on delayed onset inflammation near injection sites due to illnesses, infections, vaccinations, or dental procedures.

British scientists, in collaboration with U.S.-based biopharmaceutical startup company Neuresta, have successfully developed a novel, elongated botulinum neurotoxin that offers a potential solution for chronic pain management without the risks of paralysis or addiction.

Galderma has launched FACE by Galderma, an aesthetic visualization tool powered by augmented reality that allows aesthetic professionals and patients to visualize injectable treatment results at the planning stage before treatment begins.

The hyaluronic acid filler is now available at aesthetic practices for consumers over the age of 21 with moderate to severe loss of jawline definition.